Core Insights - Robertet is investing in Aethera Biotech to enhance its capabilities in plant-based biotechnologies, with a joint venture planned to be 50-50 owned by both companies in the long term [1][2] Group 1: Investment Details - The investment in Aethera Biotech will occur in two phases over three years, contingent on undisclosed market conditions [1] - Financial terms of the deal have not been disclosed [1] Group 2: Company Background - Aethera Biotech, founded in 2016 and based in Camisano Vicentino, Italy, specializes in producing active ingredients for the cosmetic and health markets through cell multiplication processes [3] - Aethera is a subsidiary of Cereal Docks Group, which focuses on primary agro-food transformation [3] Group 3: Biotechnology Strategy - The partnership aims to develop advanced cosmetic active ingredients, reflecting a targeted biotech strategy [2] - Aethera's proprietary CROP platform allows for the secure production of natural extracts in controlled conditions, independent of external factors [4] Group 4: Environmental Impact - The CROP platform significantly reduces environmental impact and offers a sustainable alternative to traditional production methods, embodying the concept of 'Augmented Naturality' [5] - This collaboration enables Robertet to strengthen its biotechnology expertise and secure sustainable access to innovative natural ingredients [6] Group 5: Leadership and Future Outlook - The joint venture aligns with Robertet's ambition to reinforce its leadership in natural ingredients and explore new pathways for innovation and growth [7]

Core Insights - Robertet has expanded its partnership with Aethera Biotech through a strategic investment, marking a significant step into biotechnology and reinforcing its commitment to innovative solutions that blend nature with technology [1][2][6] Company Overview - Robertet, founded in 1850, is a global leader in natural products, operating in over 50 countries with more than 2,500 employees and generating net global revenue exceeding €807 million in 2024 [9] - Aethera Biotech, established in 2016, specializes in the research and production of active ingredients from cell multiplication processes, primarily for the cosmetics and health markets [3][10] Strategic Partnership - The joint venture between Robertet and Aethera Biotech aims to create synergies by combining Aethera's advanced platform and production capabilities with Robertet's global reach and commercial expertise [2][5] - This partnership will enable Robertet to enter the market for topical cosmetic active ingredients and strengthen its biotechnology expertise [7][8] Technological Innovation - Aethera Biotech's proprietary CROP® technology allows for the secure production of natural extracts in controlled conditions, significantly reducing environmental impact and offering a sustainable alternative to traditional methods [4][6] - The collaboration is expected to accelerate innovation in skin science, aligning with Robertet's "Augmented Naturality" strategy [8] Future Growth Potential - The investment will be completed in two phases over a three-year period, supporting long-term growth by commercializing Aethera's portfolio through Robertet's global distribution network [5][7] - The partnership is anticipated to enhance Robertet's position in the cosmetic active ingredients market and boost long-term growth through a unique range of products [6][8]